A Phase 3, Multicenter, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Sickle Cell Disease
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 07 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Feb 2017 New trial record